primary hypogonadism

pri·mar·y hy·po·go·nad·ism

defective gonadal development or function, or both, due to abnormality or loss of the gonad itself.
References in periodicals archive ?
Food and Drug Administration (FDA) in May 2014 for replacement therapy in adult men with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).
The FDA has approved Natesto in May this year for replacement therapy in males for conditions related to a deficiency or lack of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
There appear to be two separate tracks to primary hypogonadism marked by testicular dysfunction: secondary hypogonadism and compensated hypogonadism.
Here, we report hormonal, molecular and cytogenetic results in an adult male patient with primary hypogonadism who was diagnosed with 46, XX male syndrome in our clinic.
If LH is elevated, the primary hypogonadism should be treated with testosterone.
Before transplantation, 3 had primary hypogonadism, and 2 had secondary hypogonadism.
The investigators excluded patients with primary hypogonadism, surgical gonadectomy, and medical conditions such as anorexia nervosa, hypothyroidism, and hypopituitarism that could lead to hypogonadism.
Interestingly, only three patients failed screening due to diagnosis of hypogonadism due to testicular dysfunction, a condition termed primary hypogonadism.
Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).
The depot formulation of testosterone undecanoate (TU), in castor oil and benzoyl benzoate, has been approved for treating adult men with primary hypogonadism or hypogonadotropic hypogonadism, congenital or acquired.
Aveed (testosterone undecanoate) injection is a schedule II controlled substance indicated for testosterone replacement therapy in adult males for the conditions associated with a deficiency or absence of endogenous testosterone of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).
AVEED injection is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired).

Full browser ?